Skip to main content
Fig. 1 | Cell Communication and Signaling

Fig. 1

From: Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer

Fig. 1

Combination therapy alleviated tumor growth, prolonged survival, and increased tumor-infiltrating NK cells in the LLC mouse model. (A) The schedule of tumor volume measurement experiment in the LLC mouse model. (B) Photographs of tumors after the different treatments on Day 22. IgG: immunoglobulin G isotype control; PD-1: PD-1 immune-checkpoint blockade antibody; SMI: SMI monotherapy; PD-1+SMI: combination of anti-PD-1 and SMI. (C) The changes of tumor volume depicted in (A) during different treatments. (D) The tumor volume of different treatments on Day 20 (n = 7). *P < 0.05, **P < 0.01. (E) The tumor weight of different treatments on Day 22 (n = 7). *P < 0.05. (F) The schedule of survival experiment in the LLC mouse model. (G) Percentage of survival of mouse during different treatments (n = 7). **P < 0.01, ***P < 0.001. (H) The proportion of tumor-infiltrating NK cells in the different treatments (n = 7). **P < 0.01

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X